Abstract:Background: The gut microbiota has been reported to play a critical role in metabolic diseases, including in diabetes. Polygonatum kingianum has been used in the treatment of diabetes and related diseases in China for centuries. Total saponins (TSPK) and total polysaccharides (PSPK) were reported to be major types of active constituents of P. kingianum. This research aims at investigation of their therapeutical mechanisms on diabetes based on the regulation of gut microbiota. Study design: Type 2 diabetes (T2D) rats were induced by high-fat diet (HFD) and streptozotocin-injection from male Sprague-Dawley (SD) rats. The blood biochemical indicators were measured. Intestinal microbial diversities and the overall structural changes in gut microbiota and the contents of the short chain fatty acids (SCFAs) were discussed. Methods: T2D rats were treated with TSPK (0.025 and 0.1g/kg) and PSPK (0.1g/kg) for 56 days. Major biochemical indexes, such as fasting blood glucose (FBG), fasting insulin (FINS) and lipopolysaccharide (LPS), were measured. Intestinal microbial diversities and the overall structural changes in gut microbiota were discussed based on the sequencing results on V4 region of 16S rDNA. Moreover, the contents of the SCFAs in faeces, which were fermentation products produced from gut microbiota were determined by gas chromatography (GC). Results: Oral administration of TSPK and PSPK prevented the increase of FBG. TSPK (0.025g/kg) enhancing the content of FINS at the end of research. Furthermore, TSPK and PSPK improved the intestinal microecology by decreasing the abundances of Bacteroidetes and Proteobacteria, and increasing that of Firmicutes. However, TSPK.L, PSPK and TSPK.H displayed discrepant regulation roles on Firmicutes. TSPK.L and PSPK significantly increased the abundance of Ruminococcaceae family and Ruminococcus genus in Firmicutes phylum, however, TSPK.H increased the abundances of Veillonellaceae family and Anaerovibrio genus. 57 Key variables, altered after treated by TSPK and PSPK, correlated to the alternations of FBG, FINS, LPS and body weight were identified. In addition, TSPK.L, PSPK and TSPK.H showed different adjustment on the contents of SCFAs. Conclusion: These results suggested that, compared to the normal rats, the structure of gut microbiota was significantly changed in diabetic rats. Oral administration with TSPK and PSPK could prevent T2D by its regulation role on the gut microbiota.

Biotransformation differences of ginsenoside compound K mediated by the gut microbiota from diabetic patients and healthy subjects

Qualitatively and quantitatively investigating the metabolism of 20(S)-protopanaxadiol-type ginsenosides by gut microbiota of different species

Bioconversion variation of ginsenoside CK mediated by human gut microbiota from healthy volunteers and colorectal cancer patients

Differences of gut microbiota between type 2 diabetes and non-diabetic population

In vivo pharmacokinetics of ginsenoside compound K mediated by gut microbiota

Personalized bioconversion of Panax notoginseng saponins mediated by gut microbiota between two different diet-pattern healthy subjects

Personalized Bioconversion of Panax Notoginseng Saponins Mediated by Gut Microbiota Between Chinese-diet and Western-diet Healthy Subjects

Biotransformation of Total Saponins in Siraitia Fructus by Human Intestinal Microbiota of Normal and Type 2 Diabetic Patients: Comprehensive Metabolite Identification and Metabolic Profile Elucidation Using LC-Q-TOF/MS.

Metabolic Analysis of Panax Notoginseng Saponins with Gut Microbiota-Mediated Biotransformation by HPLC-DAD-Q-TOF-MS/MS

Insights into gastrointestinal microbiota-generated ginsenoside metabolites and their bioactivities

Comparative analysis of the gut microbiota in people with different levels of ginsenoside Rb1 degradation to compound K

In Vivo Metabolic Profiles of Panax Notoginseng Saponins Mediated by Gut Microbiota in Rats

Identification and Quantitative Investigation of the Effects of Intestinal Microflora on the Metabolism and Pharmacokinetics of Notoginsenoside Fc Assayed by Liquid Chromatography with Electrospray Ionization Tandem Mass Spectrometry

Understanding the gut–kidney axis among biopsy-proven diabetic nephropathy, type 2 diabetes mellitus and healthy controls: an analysis of the gut microbiota composition

Quantification of Panax Notoginseng Saponins Metabolites in Rat Plasma with in Vivo Gut Microbiota-Mediated Biotransformation by HPLC-MS/MS

Metabolic Characteristics of Ginsenosides from Panax Ginseng in Rat Feces Mediated by Gut Microbiota.

Gut Microbiota: Therapeutic Targets of Ginseng Against Multiple Disorders and Ginsenoside Transformation

Intake of total saponins and polysaccharides from Polygonatum kingianum affects the gut microbiota in diabetic rats

Effect of Gut Microbiota on the Metabolism of Chemical Constituents of Berberis kansuensis Extract Based on UHPLC-Orbitrap-MS Technique

Effects of Danggui Buxue decoction on host gut microbiota and metabolism in GK rats with type 2 diabetes

Comparative Investigation of in Vitro Biotransformation of 14 Components in Ginkgo Biloba Extract in Normal, Diabetes and Diabetic Nephropathy Rat Intestinal Bacteria Matrix.